Sugi Predict

Sugi Predict / Compounds / SCHEMBL403254

SCHEMBL403254

SCHEMBL403254

N[C@@H](Cc1cccc(S)c1)C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 9/20 0.65
▸ PTGS1 P23219 2/20 0.65
▸ ALPI P09923 1/20 0.65
▸ PKM P14618 1/20 0.65
▸ XIAP P98170 1/20 0.65
▸ GRIA2 P42262 1/20 0.60
▸ NOS3 P29474 3/20 0.59
▸ NOS1 P29475 3/20 0.59
▸ NOS2 P35228 3/20 0.59
▸ KDM4E B2RXH2 1/20 0.56
▸ USP2 O75604 1/20 0.56
▸ EGFR P00533 1/20 0.56
▸ LCK P06239 1/20 0.56
▸ FYN P06241 1/20 0.56
▸ ADORA3 P0DMS8 1/20 0.56
▸ ALOX15 P16050 1/20 0.56
▸ HTR2A P28223 1/20 0.56
▸ PTGS2 P35354 1/20 0.56
▸ RECQL P46063 1/20 0.56
▸ HIF1A Q16665 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20298379 1.00 SLC7A5 (0.65) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL403255 1.00 SLC7A5 (0.65) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL31453790 1.00 SLC7A5 (0.65) SLC7A5PTGS1ALPIPKMXIAP
Ornithine SCHEMBL4292703 0.89 SLC7A5 (0.51) SLC7A5PTGS1ALPIPKMXIAP
Ornithine Aketoglutarate SCHEMBL4292700 0.89 SLC7A5 (0.51) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL2314258 0.87 SLC7A5 (0.77) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL26010520 0.83 GRIK1 (0.51) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL17785191 0.83 SLC7A5 (0.65) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL11392062 0.83 GRIA2 (0.42) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL17785190 0.83 SLC7A5 (0.65) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122070294-A Stable vitreous material based on histidine, arginine and glutamic acid amino acids 阵序补丁有限公司 2026-05-19 — — CN claimed
WO-2025032025-A1 STABLE GLASSY MATERIAL BASED ON HISTIDINE, ARGININE AND GLUTAMIC ACID AMINO ACIDS VITROPEP (FR) 2025-02-13 — — WO claimed
US-20090111743-A1 Cysteine-branched heparin-binding growth factor analogs BIOSURFACE ENGINEERING TECHNOLOGIES, INC. (US) 2009-04-30 — — US claimed
US-20080227696-A1 Single branch heparin-binding growth factor analogs BIOSURFACE ENGINEERING TECHNOLOGIES, INC. (US) 2008-09-18 — — US claimed
EP-1379283-B1 IDENTIFICATION OF TARGET-SPECIFIC FOLDING SITES IN PEPTIDES AND PROTEINS PALATIN TECHNOLOGIES INC (US) 2008-02-13 — — EP claimed
EP-1855706-A2 SINGLE BRANCH HEPARIN-BINDING GROWTH FACTOR ANALOGS Biosurface Engineering Technologies, Inc. (US) 2007-11-21 — — EP claimed
EP-1594442-A4 KNOCKOUT IDENTIFICATION OF TARGET-SPECIFIC SITES IN PEPTIDES PALATIN TECHNOLOGIES INC (US) 2007-08-01 — — EP claimed
WO-2006091727-A2 SINGLE BRANCH HEPARIN-BINDING GROWTH FACTOR ANALOGS BIOSURFACE ENGINEERING TECHNOLOGIES, INC. (US) 2006-08-31 — — WO claimed
EP-1425029-A4 PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES PALATIN TECHNOLOGIES INC (US) 2006-06-07 — — EP claimed
EP-1594442-A2 KNOCKOUT IDENTIFICATION OF TARGET-SPECIFIC SITES IN PEPTIDES Palatin Technologies, Inc. (US) 2005-11-16 — — EP claimed
JP-2005504043-A — — 2005-02-10 — — JP claimed
US-20050014193-A1 Identification of target-specific folding sites in peptides and proteins SHARMA SHUBH D (US) 2005-01-20 — — US claimed
EP-1379283-A4 IDENTIFICATION OF TARGET-SPECIFIC FOLDING SITES IN PEPTIDES AND PROTEINS PALATIN TECHNOLOGIES INC (US) 2005-01-19 — — EP claimed
US-20040248212-A1 Knockout identification of target-specific sites in peptides PALATIN TECHNOLOGIES, INC. (US) 2004-12-09 — — US claimed
WO-2004075830-A2 KNOCKOUT IDENTIFICATION OF TARGET-SPECIFIC SITES IN PEPTIDES PALATIN TECHNOLOGIES, INC. (US) 2004-09-10 — — WO claimed
US-20040171520-A1 Peptidomimetics of biologically active metallopeptides PALATIN TECHNOLOGIES, INC. 2004-09-02 — — US claimed
EP-1425029-A1 PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES Palatin Technologies, Inc. (US) 2004-06-09 — — EP claimed
EP-1379283-A2 IDENTIFICATION OF TARGET-SPECIFIC FOLDING SITES IN PEPTIDES AND PROTEINS Palatin Technologies, Inc. (US) 2004-01-14 — — EP claimed
WO-2003013571-A1 PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES PALATIN TECHNOLOGIES, INC. (US) 2003-02-20 — — WO claimed
WO-2002064734-A2 IDENTIFICATION OF TARGET-SPECIFIC FOLDING SITES IN PEPTIDES AND PROTEINS PALATIN TECHNOLOGIES, INC. (US) 2002-08-22 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171520-A1 Peptidomimetics of biologically active metallopeptides MC1R, MC4R, MC5R SLC7A5 475/4885PTGS1 2140/4885ALPI 3150/4885
US-20080227696-A1 Single branch heparin-binding growth factor analogs HDGF, HGF, FGF2 SLC7A5 1813/4885PTGS1 1371/4885ALPI 3311/4885
US-20090111743-A1 Cysteine-branched heparin-binding growth factor analogs HDGF, IGFBP1, IGFBP4 SLC7A5 534/4885PTGS1 985/4885ALPI 2186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.